Get started
MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC

MARINUS PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MRNS chart


Full chart

MRNS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪265.06 M‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−48.63 MXN
Net income (FY)
‪−2.40 B‬ MXN
Revenue (FY)
‪526.35 M‬ MXN
Shares float
‪41.87 M‬
Beta (1Y)
4.02

Employees


Employees (FY)
165
Change (1Y)
+14 +9.27%
Revenue / Employee (1Y)
‪3.19 M‬ MXN
Net income / Employee (1Y)
‪−14.56 M‬ MXN

About Marinus Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Scott N. Braunstein
Headquarters
Radnor
Website
marinuspharma.com
Founded
2003
FIGI
BBG00JCHDDZ6
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRNS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MRNS is 5.25 MXN — it has decreased by −9.48% in the past 24 hours. Watch MARINUS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange MARINUS PHARMACEUTICALS INC stocks are traded under the ticker MRNS.
MRNS stock has fallen by −19.23% compared to the previous week, the month change is a −25.00% fall, over the last year MARINUS PHARMACEUTICALS INC has showed a −96.14% decrease.
We've gathered analysts' opinions on MARINUS PHARMACEUTICALS INC future price: according to them, MRNS price has a max estimate of 61.60 MXN and a min estimate of 6.16 MXN. Watch MRNS chart and read a more detailed MARINUS PHARMACEUTICALS INC stock forecast: see what analysts think of MARINUS PHARMACEUTICALS INC and suggest that you do with its stocks.
MRNS reached its all-time high on Sep 25, 2018 with the price of 2,784.00 MXN, and its all-time low was 5.25 MXN and was reached on Dec 19, 2024. View more price dynamics on MRNS chart.
See other stocks reaching their highest and lowest prices.
MRNS stock is 10.48% volatile and has beta coefficient of 4.02. Track MARINUS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is MARINUS PHARMACEUTICALS INC there?
Today MARINUS PHARMACEUTICALS INC has the market capitalization of ‪265.07 M‬, it has decreased by −9.40% over the last week.
Yes, you can track MARINUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
MARINUS PHARMACEUTICALS INC is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
MRNS earnings for the last quarter are −8.28 MXN per share, whereas the estimation was −8.06 MXN resulting in a −2.64% surprise. The estimated earnings for the next quarter are −5.99 MXN per share. See more details about MARINUS PHARMACEUTICALS INC earnings.
MARINUS PHARMACEUTICALS INC revenue for the last quarter amounts to ‪168.29 M‬ MXN, despite the estimated figure of ‪185.64 M‬ MXN. In the next quarter, revenue is expected to reach ‪228.89 M‬ MXN.
MRNS net income for the last quarter is ‪−477.32 M‬ MXN, while the quarter before that showed ‪−657.15 M‬ MXN of net income which accounts for 27.37% change. Track more MARINUS PHARMACEUTICALS INC financial stats to get the full picture.
No, MRNS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 165.00 employees. See our rating of the largest employees — is MARINUS PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MARINUS PHARMACEUTICALS INC EBITDA is ‪−2.41 B‬ MXN, and current EBITDA margin is −422.52%. See more stats in MARINUS PHARMACEUTICALS INC financial statements.
Like other stocks, MRNS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MARINUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MARINUS PHARMACEUTICALS INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MARINUS PHARMACEUTICALS INC stock shows the sell signal. See more of MARINUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.